Your browser does not support JavaScript or it may be disabled!
rediff.com
 India As It Happens
Rediff Labs will showcase innovative products that rediff is working on behind the scenes.
News   |   Images
NEWS ON MOBILE
Get Realtime News
on your webpage

About 814 results for "gilead sciences"

Brocade Communications Systems, Inc. (NASDAQ:BRCD) & Gilead Sciences, Inc. (NASDAQ:GILD) Stocks in the Spotlight
News Is Money

Gilead Sciences Nears 30-Month Low, Attempts To Rebound

Gilead Sciences, Inc. (NASDAQ: GILD ) shares are trading lower by $0.07 at $72.40 in Wednesday's session. Earlier in the session, the issue was lower as the entire sector was under pressure following a statement by Donald Trump that he intends to ... Benzinga.com, 22 hours ago
Gilead Just Not Living Up To Expectations Seeking Alpha, 2 days ago
[x]  

462 images for gilead sciences

American Banking News, 5 days ago
Investing.com, 10 minutes ago
SleekMoney, 8 hours ago
SleekMoney, 3 days ago
Nasdaq, 3 days ago
WKRB News, 2 weeks ago
Yahoo! Canada, 2 weeks ago
Morningstar.com, 2 weeks ago
News Is Money, 1 day ago
Yahoo! Finance, 3 days ago
Nasdaq

Gilead Sciences Submits NDA For SOF/VEL/VOX - Quick Facts

The NDA for SOF/VEL/VOX is based on data from two Phase 3 studies (POLARIS-1 and POLARIS-4), which evaluated 12 weeks of the fixed-dose combination in DAA-experienced patients with hepatitis C genotypes 1-6, including those who failed prior ...
 Nasdaq1 hour ago Gilead Submits New Drug Application to U.S. Food and Drug Administration for the Investigational Single Tablet Regimen Sofosbuvir/Velpatasvir/Voxilaprevir  Business Wire1 hour ago BRIEF-Gilead Sciences submits new drug application to U.S. FDA for Hepatitis C  Reuters UK42 minutes ago GILEAD SCIENCES : Submits New Drug Application to U.S. Food and Drug Administration for the Investigational Single Tablet Regimen Sofosbuvir/Velpatasvir/Voxilaprevir  4 Traders1 hour ago
[x]  
Investing.com

Gilead Sciences Bucks Biotech Trend

While the stock market hit all-time highs on Wednesday, the biotechnology sector took a beating. This was on the back of comments from Donald Trump over curbing drug prices. While a majority of biotech stocks were down sharply, there was one that ...
 Investing.com14 minutes ago Biotech Stocks Under Review -- Novavax, Gilead Sciences, Ariad Pharma, and Exelixis  Nasdaq2 weeks ago Biotech Stocks Under Review Novavax Gilead Sciences Ariad Pharma and Exelixis  Pharma Focus Asia2 weeks ago Biotech Stocks Under Review — Novavax, Gilead Sciences, Ariad Pharma, and Exelixis  Freshnews.com2 weeks ago
[x]  
Yahoo! Finance

Gilead Sciences Inc.'s Worst Moves in 2016

As 2016 draws to a close, we all tend to look back on the good and the bad experienced during another trip around the sun. Unfortunately for Gilead Sciences ( NASDAQ:GILD ) , there were plenty of bad things that happened this year. Some of the ...
 Motley Fool1 day ago
[x]  
Yahoo! Finance

3 Beaten-Up Healthcare Stocks: Are They Bargains?

More Bristol-Myers Squibb and Gilead Sciences are strong buys after a poor 2016. But Dynavax is probably best avoided after its steep drop-off
 Yahoo! Finance2 days ago

Gilead Sciences: Nothing to See Here…Except the Need for M&A

After Gilead Sciences (GILD) provided updates on its Bruton's tyrosine kinase, or BTK, and spleen tyrosine kinase, or Syk, hematology programs American Society of Hematology, Credit Suisse analyst
 Yahoo! Finance2 days ago
[x]  
Motley Fool

1 Quote Reveals Why Gilead Sciences Hasn't Bought Anybody Yet

Gilead Sciences ( NASDAQ:GILD ) needs to buy somebody. The Hepatitis C / HIV behemoth has seen its price tank in 2016 as investor fears about growth slowing -- and even reversing -- have come true. Slashing prices to maintain its Hepatitis C ...
 Motley Fool3 days ago
Motley Fool

5 Dividend Stocks to Buy in December

More Want to add some dividends to your portfolio in December? Check out Amgen, Gilead Sciences, American Tower, Enterprise Products Partners, and
 Yahoo! Finance4 days ago
Washington Blade

Switching course, Gilead markets HIV drug for prevention

By Jilian Mincer NEW YORK, Nov 30 (Reuters) - Gilead Sciences Inc has begun marketing its HIV treatment Truvada in a way thousands of consumers already use it - to prevent infection with the virus that causes AIDS. The company introduced Truvada ...
 Yahoo! Finance1 week ago Injections to be used in HIV prevention in Africa  Washington Blade4 days ago Injections that can keep HIV at bay for 2 months being tested  Deccan Chronicle1 week ago Injections, implants tested as new weapons to prevent HIV  HealthMediciNet.com1 week ago
[x]  

Gilead Sciences Needs To Use Its Cash - Cramer's Lightning Round (11/22/16)

Cramer likes Worthington Industries and Nucor. Don't buy Public Storage. Stocks discussed on the Lightning Round segment of Jim Cramer's Mad Money Program, Tuesday, November 22. Bullish Calls Devon Energy (NYSE:DVN): It's fine but there are ...
 Seeking Alpha2 weeks ago Cramer's lightning round: Why I'm wary of Gilead's growth  Yahoo! Canada1 week ago
[x]  
Prev | Next
Personalize your Realtimeclose [x]
Add content to your personalized tab - My News
Add upto 6 topics of your interest:
for eg.2g Scam , World
1.
2.
3.
4.
5.
6.
Personalize the tabs display. ( You can add or remove the tabs )
AlertsGet updates on latest news & your favourite topics right in your inbox.Set an Alert|Manage your Alerts

Get

Realtime News

on your Webpage

Add Widget >Get your members hooked!
    
Alerts
Get updated on latest news & your favorite topics right in your inbox!
 
More     Less